EML4 and lung carcinoma: On July 23, 2018, secondary gene detection was performed after 5 months of first-line treatment, and mutation analysis of lung cancer 56 gene was performed using Capture-based NGS testing: EML4-ALK (E18: A20) gene fusion, abundance 49.37%; ALK exon 25 p. G1269A missense mutation, abundance 3.62%; and ALK exon 23 p. R1192 missense mutation, abundance 4.10%.